Year: 2012
Type: article
Study design: Observational Study
Abstract: When the Fremantle Diabetes Study (FDS) Phase I was conceived in 1991 by its chief investigator (T.M.E.D.), there were few published longitudinal community-based diabetes natural history studies. Population studies such as Framingham1 in the United States and Busselton2 in Australia contained relatively small subgroups from which limited additional diabetes-specific information was collected. The United Kingdom Prospective Diabetes Study (UKPDS) had recruited more than 5000 newly diagnosed type 2 subjects aged 25–65 years but the sample, although relatively large, was not community based. The diagnosis of diabetes was based on a low fasting plasma glucose concentration (>6 mmol/l), and the study was interventional with outcomes presented in 1998.3 There were also Australia-specific aspects of diabetes that had not been characterized in detail, especially the disproportionately large number of patients from a migrant (especially Southern European) background4 and the important question of diabetes in indigenous groups.5 The aim of FDS Phase I was, therefore, to identify from all potential sources, and collect detailed prospective data from, known diabetic patients in a stable multi-ethnic urban Australian population to examine clinically relevant aspects of diabetes including clinical management, metabolic control, complications and cost. Based on the amount of available seeding funding from the Raine Foundation, University of Western Australia (WA) and respecting a reasonable patient time commitment and throughput, it was decided to attempt to recruit all consenting patients from the Fremantle Hospital (FH) primary catchment area, a postcode-defined population of approximately 120 000 living in and around the port of Fremantle in Western Australia. A 3-year registration period between 1993 and 1996 was followed by yearly reviews of the FDS Phase I cohort until 2001 (a minimum follow-up of 5 years) by which time more than half of the patients had died or withdrawn, although acquisition of hospitalizations, cancer registrations and deaths through the WA Data Linkage System (WADLS)6 has continued since. During and after the active data collection in Phase I, the results of a number of studies were published that provided important data relating to diabetes epidemiology and management. The Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study7 showed that the prevalence of diabetes had increased at the rate of 0.15%/year in males and 0.18%/year in females in individuals aged ≥25 years during the 19 years since the first Australian estimate from the Busselton survey in 1981.2 The incidence of type 1 diabetes in Australia was also increasing.8 A contributor to this increased prevalence was the lowering of the threshold fasting plasma glucose for diagnosis of diabetes from 7.8 mmol/l to 7.0 mmol/l by the World Health Organization in 1999.9 In relation to management, results of the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes were first presented in 1993 and confirmed the benefits of tight glycaemic control in the prevention of microvascular disease.10 Parallel findings for type 2 diabetes from the UKPDS followed in 19983,11 but the UKPDS also highlighted the vascular benefits of intensive management of hypertension.12 Other landmark non-glycaemic intervention trials, such as the Heart Outcomes Prevention Evaluation (HOPE and MICRO-HOPE),13 the Heart Protection Study14 and the Fenofibrate Intervention and Event Lowering in Diabetes Study15 provided further evidence of the benefits of individual intensive vascular risk factor management in type 2 diabetes. The Steno-2 Study extended these findings in a multifactorial intervention that reduced both micro- and macrovascular disease.16 In addition, the 33% 2-year mortality rate in conventionally treated diabetic patients after myocardial infarction in the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study carried out in the early 1990s17 had fallen to 19% in similar patients in the more recent DIGAMI-2 Study18 in the presence of increased use of aspirin, β-blockers, ACEI and especially statin therapy. These studies were likely to have influenced changes in management of Australian diabetic patients during and after the active data collection in Phase I. Although findings from Phase I had contributed to an understanding of the natural history of diabetes, the changes in diabetes epidemiology and management justified a Phase II that duplicated and extended data collection. Funding for this new study was obtained from the National Health and Medical Research Council of Australia and it started in the first part of 2008, some 15 years after the first patient was recruited to Phase I. The Phase II baseline cohort was recruited over a 3-year period from the same catchment area using similar methods of ascertainment as Phase I. Longitudinal follow-up data collection is continuing at present. The samples for Phases I and II have been drawn from the same geographical area. From Australian Bureau of Statistics data,19 there were 120 000 people in the postcode-defined catchment area at the start of Phase I in 1993 and 153 000 in 2008 at the start of Phase II. In addition to a 28% increase in the population during the 15 years between Phases I and II, the demography and ethnic mix have changed. For example, the percentage born in Southern Europe has fallen from 7.4% to 2.5% and the mean age has increased with those aged ≥50 years comprising 30.7% compared with 25.6% in 1993. In Phase I, diabetic patients residing in the study catchment area were identified from FH clinic and inpatient lists, local physician referrals, allied health facilities, pharmacies, opticians, advertising in local media and word of mouth. Of 2258 potential subjects identified during registration between 1993 and 1996, 1426 (63%) were recruited.20,21 This compares favourably with the AusDiab Study, which recruited 41% of randomly selected households and obtained biomedical data from 56% of identified individuals within them.7 A range of baseline and outcome data was also collected from the 832 patients who were identified but not recruited to provide an objective assessment of the representative nature of the sample. Eligible patients who declined participation were a mean of 1.4 years older than participants, but their country of birth, sex distribution and the distributions of diabetes types and treatment modalities were similar.20,21 For Phase II, recruitment strategies were the same as those used in Phase I except that third-party mail-outs of potentially eligible patients were arranged through the Australian National Diabetes Services Scheme and National Diabetes Register. A consort diagram that summarizes recruitment is shown in Figure 1. There were 4952 diabetic patients identified between 2008 and 2011, including 796 original Phase I surviving participants of whom 168 had moved out of the study area but from whom long-term follow-up data were being sought. A total of 1732 (35.0%) subjects were recruited to Phase II (including 64 non-resident Phase I subjects), a lower rate than Phase I but still higher than AusDiab.7 Exclusion of the out-of-area participants left 4784 identified and residing within the study area with 1668 (34.9%) of these recruited. Consort diagram showing patient recruitment for both phases of the FDS As in Phase I, data are being collected to characterize as many non-recruited patients as possible from all possible sources (Table 1). Phase II non-recruited subjects were a mean of 1.2 years younger than participants at the start of recruitment but their sex distribution was similar with just over 50% males. Available preliminary data for other variables including ethnicity do not show marked differences. Comparison of characteristics of diabetic residents recruited to and not recruited to FDS Phase II, including those who also participated in Phase I (data as at April 2012) aEthnic background for 2496 newly identified diabetic patients who were not recruited to Phase II was based on the country of patient’s birth only, compared with self-selection, country of the patient’s birth, country of father's/mother's birth and language spoken at home in Phase I. bAge and duration of diabetes were as at 18 Feb 2008 (start of Phase II). cData are for 1459 new non-recruits to Phase II. dProjected for those who died before Phase II started. eData are median and (inter-quartile range). *P < 0.05, **P < 0.01, ***P < 0.001 (Phase II recruits as reference), #P < 0.05, ##P < 0.01, ###P < 0.001 (Phase II non-recruits as reference). Pairwise comparisons (other than for variables with incomplete data) unadjusted for multiple comparisons. Comparison of characteristics of diabetic residents recruited to and not recruited to FDS Phase II, including those who also participated in Phase I (data as at April 2012) aEthnic background for 2496 newly identified diabetic patients who were not recruited to Phase II was based on the country of patient’s birth only, compared with self-selection, country of the patient’s birth, country of father's/mother's birth and language spoken at home in Phase I. bAge and duration of diabetes were as at 18 Feb 2008 (start of Phase II). cData are for 1459 new non-recruits to Phase II. dProjected for those who died before Phase II started. eData are median and (inter-quartile range). *P < 0.05, **P < 0.01, ***P < 0.001 (Phase II recruits as reference), #P < 0.05, ##P < 0.01, ###P < 0.001 (Phase II non-recruits as reference). Pairwise comparisons (other than for variables with incomplete data) unadjusted for multiple comparisons. In Phase I, baseline and subsequent annual assessments were performed until death, withdrawal, relocation out of the study area or the close-out of individual patient data collection in 2001 (Table 2). The WADLS was established in 1995 to connect all available health and related information for the WA population.6 The FDS has been linked with the WADLS since 2001 and continues to receive regular data updates. The latest regular update was in early 2011, providing up to 17 years of follow-up of our Phase I cohort. Data collections linked by WADLS include core datasets comprising the Hospital Morbidity Data Collection (HMDC; since 1970), Emergency Department Data Collection (since 2002), Western Australian Cancer Registry (since 1982) and the Death Register (since 1969). Linkage has also been possible with Silver Chain22 (one of the largest providers of community and health services to the WA community) and St John Ambulance23 (the main ambulance provider in Western Australia) in collaboration with their respective data custodians but facilitated by the WADLS. The Metropolitan Cemeteries Board24 database and individual hospital case notes have also complemented and validated linkage data. Longitudinal demographic data of FDS Phase I participants and reasons for loss to follow-up aThere were 317 (22.2%) deaths by 1 November, 2001 (end Phase I active follow-up); 603 (42.3%) before Phase II baseline assessments started on 18 February, 2008 and 727 (51.0%) before Phase II baseline assessments closed; deaths counted in each year if they occurred within 1.5 years of the last assessment. bIn Phase II, categorization of type of diabetes was not constrained with respect to age at diagnosis but, for comparison purposes, the Phase I classification is presented. cIn Phase II, grandparent country of birth (COB) was ascertained in addition to participant and parents’ COB leading to an increase in category 5 (mixed). For comparison purposes, the Phase I classification is presented. dMoved overseas during Phase I. e≥1.5 years from last visit to last Phase I assessment date (1 November 2001). f<1.5 years from last visit to 1 November 2001. gOther = no response/return to sender/not on electoral roll (n = 115), poor health (n = 5). Longitudinal demographic data of FDS Phase I participants and reasons for loss to follow-up aThere were 317 (22.2%) deaths by 1 November, 2001 (end Phase I active follow-up); 603 (42.3%) before Phase II baseline assessments started on 18 February, 2008 and 727 (51.0%) before Phase II baseline assessments closed; deaths counted in each year if they occurred within 1.5 years of the last assessment. bIn Phase II, categorization of type of diabetes was not constrained with respect to age at diagnosis but, for comparison purposes, the Phase I classification is presented. cIn Phase II, grandparent country of birth (COB) was ascertained in addition to participant and parents’ COB leading to an increase in category 5 (mixed). For comparison purposes, the Phase I classification is presented. dMoved overseas during Phase I. e≥1.5 years from last visit to last Phase I assessment date (1 November 2001). f<1.5 years from last visit to 1 November 2001. gOther = no response/return to sender/not on electoral roll (n = 115), poor health (n = 5). At the beginning of Phase II recruitment in mid-February 2008, 603 (42.3%) of the original Phase I cohort had died and 27 were lost to follow-up (18 had definitely/probably moved overseas or interstate, whereas the whereabouts of 9 was unknown). By the end of Phase II recruitment at end-June 2011, a further 124 had died, 106 of whom were unable to be recruited to Phase II out of the remaining 406 Phase I patients (Table 2). In summary, <2% of the original cohort is no longer providing data for analyses. Table 1 compares the characteristics of Phase I participants who (i) were recruited to Phase II, (ii) were alive at the start of Phase II recruitment and had not been lost to follow-up but who were not recruited and (iii) either died before Phase II started or were lost to follow-up before Phase I. In Phase II, baseline and subsequent biennial detailed assessments will be performed until death or withdrawal, but questionnaires are being sent out every second year to gather data, including those relating to changes in management and the development of complications and co-morbidities, to complement full in-person data collection. In contrast to Phase I, relocation out of the study area will not be a criterion for cessation of active data collection. As the recruitment period for Phase II only recently closed, there has been insufficient time for an assessment of attrition in this cohort. The data collected at baseline and at each subsequent visit (annually for Phase I and biennially for Phase II) are summarized in Table 3. Data collection in FDS Phases I and II Demographic details Diabetes-related information Current lifestyle measures—in Phase II, this includes specific validated questionnaires relating to diet25,26 and physical activity27,28 Availability of, and access to, care Knowledge of diabetes—including a validated knowledge test in both Phases29 General medical information —including, in Phase II, a family history of diseases30 and Berlin sleep31 questionnaires Current health status—ascertained by General Health Questionnaire32 in Phase I and by multiple validated instruments33–36 in Phase II Cognitive function, mood and activities of living and if for Phase II, the and other validated of from health and linkage to WADLS and in Phase II, by for studies for of and relevant to the clinical in Phase II Phase II a randomly selected of 50% of Phase II a of Phase II patients with Berlin that are either low risk or risk for and and and at baseline (Phase (Phase II) and of of remaining and at for further Demographic details Diabetes-related information Current lifestyle measures—in Phase II, this includes specific validated questionnaires relating to diet25,26 and physical activity27,28 Availability of, and access to, care Knowledge of diabetes—including a validated knowledge test in both Phases29 General medical information —including, in Phase II, a family history of diseases30 and Berlin sleep31 questionnaires Current health status—ascertained by General Health Questionnaire32 in Phase I and by multiple validated instruments33–36 in Phase II Cognitive function, mood and activities of living and if for Phase II, the and other validated of from health and linkage to WADLS and in Phase II, by for studies for of and relevant to the clinical in Phase II Phase II a randomly selected of 50% of Phase II a of Phase II patients with Berlin that are either low risk or risk for and and and at baseline (Phase (Phase II) and of of remaining and at for further Data collection in FDS Phases I and II Demographic details Diabetes-related information Current lifestyle measures—in Phase II, this includes specific validated questionnaires relating to diet25,26 and physical activity27,28 Availability of, and access to, care Knowledge of diabetes—including a validated knowledge test in both Phases29 General medical information —including, in Phase II, a family history of diseases30 and Berlin sleep31 questionnaires Current health status—ascertained by General Health Questionnaire32 in Phase I and by multiple validated instruments33–36 in Phase II Cognitive function, mood and activities of living and if for Phase II, the and other validated of from health and linkage to WADLS and in Phase II, by for studies for of and relevant to the clinical in Phase II Phase II a randomly selected of 50% of Phase II a of Phase II patients with Berlin that are either low risk or risk for and and and at baseline (Phase (Phase II) and of of remaining and at for further Demographic details Diabetes-related information Current lifestyle measures—in Phase II, this includes specific validated questionnaires relating to diet25,26 and physical activity27,28 Availability of, and access to, care Knowledge of diabetes—including a validated knowledge test in both Phases29 General medical information —including, in Phase II, a family history of diseases30 and Berlin sleep31 questionnaires Current health status—ascertained by General Health Questionnaire32 in Phase I and by multiple validated instruments33–36 in Phase II Cognitive function, mood and activities of living and if for Phase II, the and other validated of from health and linkage to WADLS and in Phase II, by for studies for of and relevant to the clinical in Phase II Phase II a randomly selected of 50% of Phase II a of Phase II patients with Berlin that are either low risk or risk for and and and at baseline (Phase (Phase II) and of of remaining and at for further questionnaires are sent out to Phase II participants in years based on the data collected in In both patients have after a with and and and plasma from care are the same in a the same has been used for both Phases or are There have been over Phase I data The by Phase I have been the these have from the of a low prevalence of diabetes of in a multi-ethnic and a poor outcome in type 2 indigenous to an assessment of the nature of type 2 diabetes in and Phase I also showed that people from Southern migrant have a prevalence of diabetes and more to than other ethnic but do not at a younger age as a in this area have from data that are that males with type 2 diabetes from in a primary prevention and that have on in community-based patients to those in clinical to the development of an Australian diabetes risk and a diabetes-specific medical data have the of of glucose in patients with type 2 and have contributed to the development of the Diabetes Acute and in relation to Phase I data have shown in with glycaemic intervention is with a higher in type 2 whereas is that diabetes but that has an in type 2 The presence of an to be a of type 2 whereas was the of first in type 1 have also confirmed that myocardial infarction is in diabetes but that the in such patients is than in those with Phase I provided some of the first data diabetes in poor glycaemic control to and to the data type 1 diabetes as a risk factor for patients with are to and whereas a history of is a of in type 2 Diabetes is a risk factor for and but the of to have been Phase I data have shown that the of diabetes in Australia over the years if with a from to non-glycaemic risk loss of important Phase I the Fremantle Diabetes and Study, which has a range of data, including evidence that older diabetic subjects have of in physical and The of both Phases of the FDS are the and representative nature of the the range and of data collection and linkage to and mortality in Western Australia in Australia as a The and of the FDS that specific the natural history of diabetes, its on the individual and its be with The main was the of patients who were not recruited or who to if this was to assessments at a The lower recruitment rate in Phase II Phase I in the of diabetes care through primary care in that of or regular metabolic and complications The FDS assessment was by some potential recruits and participants as a of this of Phase I, which of the time it was have been in Phase II, including (i) of an health to recruitment and follow-up of indigenous patients recruited to Phase II compared with only in Phase (ii) third-party mail-outs through that the number of people in the catchment area with diabetes as as (iii) of questionnaires to be in and the time commitment 2 and if data were of home assessments for patients unable to FH and of assessment for The of and range of data to be collected in a study such as FDS are by and but clinically important of diabetes on outcomes be if the is attrition from natural and patient withdrawal, such as that which occurred in Phase I, be in to recruitment and on time which be reduced if are in patients to through assessments and to as those from an indigenous is as by an increase in participants from of the cohort in Phase I to in Phase II. FDS data are and to of this is intervention are there is evidence that such in studies are or from, those obtained in the evidence for management of such as diabetes, but studies be or have incomplete or are include recruitment of the or those with multiple complications and be over a period of The data are in a which only be by of the FDS The data is the FDS with the chief investigator (T.M.E.D.), is the main of The FDS has a with similar data who to or or The FDS was by the Raine Foundation, University of Western Australia (Phase and the National Health and Medical Research Council of Australia. is by a are to FDS for with and clinical the Department at Fremantle Hospital and Health for and the and for with recruitment of The WADLS is for of and mortality data. of a range of the FDS has the to the ethnic patients of Southern migrant have a prevalence of type 2 diabetes and more to and Australian with diabetes have glycaemic control and a poor are and males with type 2 diabetes from in a primary prevention Diabetes but vascular has an in type 2 diabetes. Diabetes in poor glycaemic control to whereas vascular and are with and in type 2 The of diabetes in Australia are likely to over the
DOI: 10.1093/ije/dys065
Authors: Timothy ME Davis, David G Bruce, Wendy A Davis
Institution: The University of Western Australia
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2115079411
